2024-02-16| M&A

GSK Completed the Acquisition of Aiolos Bio, Enhancing the Respiratory Portfolio of Asthma

by Oscar Wu
Share To

Following the GlaxoSmithKline (GSK) announcement to buy asthma drugmaker Aiolos Bio for $1.4 billion at the J.P. Morgan Healthcare Conference, GSK completed the acquisition of Aiolos Bio on 15 February 2024.

The acquisition includes AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody for treating asthma. The terms of agreement includes a $1 billion upfront payment and up to $400 million in certain success-based regulatory milestone payments. Through this acquisition, GSK’s respiratory portfolio expands and complements its existing medicines and vaccines for respiratory conditions.

(Source: please see References; Table: GeneOnline)

A Closer Look at AIO-001: A Novel Antibody Targeting Asthma Inflammation

At the heart of AIO-001’s mechanism of action lies a protein called Thymic Stromal Lymphopoietin (TSLP). TSLP is a cytokine, a type of signaling molecule in the immune system, responsible for igniting a cascade of inflammatory events.  It plays a particularly important role in allergic inflammation, a hallmark of asthma.

As a monoclonal antibody, AIO-001 is a laboratory-produced molecule that functions like naturally-occurring antibodies in the immune system.  AIO-001 is engineered to specifically recognize and bind with high affinity to TSLP. This binding neutralizes TSLP, preventing it from activating its receptor on immune cells.

The potential benefits of AIO-001’s upstream intervention are significant. By targeting TSLP, AIO-001 may reduce the production of a wide range of inflammatory cytokines, dampen the recruitment of immune cells involved in allergic inflammation, and lessen the airway changes often associated with chronic asthma. Further, thanks to its unique ability to neutralize TSLP over extended periods,  AIO-001 could offer very infrequent dosing schedules, a  potential improvement for patient convenience.

While these prospects are exciting, it’s essential to remember that AIO-001 is still an investigational drug. Ongoing clinical trials are necessary to determine its long-term safety and efficacy thoroughly. Yet,  AIO-001 represents a potentially groundbreaking approach to asthma treatment, highlighting the exciting advancements in targeting specific immune pathways that drive this complex disease.

AIO-001 now is exclusively licensed to Aiolos for development and commercialization rights outside of Greater China by Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui).

© All rights reserved. Collaborate with us:
Related Post
Asthma Medications: From Quick Relief to Long-Term Control
JPM 2024: GSK Buys Aiolos Bio for $1.4 Billion, Cytokinetics Acquisition Sparks Three-way Contest
AstraZeneca’s severe asthma drug Tezspire has been granted market authorization in South Korea
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top